Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Generalized Anxiety Disorders (GAD) TherapeuticsGAD Therapeutics Market is Forecast to Show Low Growth until 2018
By: Rajesh Gunnam GlobalData’s research indicates that the current market is served by US Food and Drug Administration (FDA)-approved drugs, off label drugs and alternative therapies such as cognitive behavioral therapy. The treatment options include selective serotonin re-uptake inhibitors (SSRI)s, selective norepinephrine reuptake inhibitors (SNRI)s, benzodiazepines, buspirone and tricyclic antidepressants (TCA)s. All have moderate safety and efficacy profiles. Patients experiencing symptoms of GAD do not generally perceive it as a disorder and as such, patients do not actively seek treatment. Instead, many patients proceed with self medication. In addition to this the diagnostic tools currently available for GAD diagnosis are not effective and this has lead to poor diagnosis rates. Overall, the GAD therapeutics market has treatment options which are currently satisfying patients but there is low treatment-seeking behavior and a low diagnosis rate. The GAD therapeutics pipeline has seven molecules in development. The late stage pipeline has only one product LuAA21004 which is expected to impact the forecast period. This product is a multimodal antidepressant whose mechanism of action is on the serotonin receptors. Therefore, this product is not expected to add to the market valuations significantly. The GAD therapeutics pipeline has molecules in the early stage of development which are not expected to impact the market in the forecast period. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ The GAD therapeutics market has moderate unmet need. This is due a low treatment-seeking rate and a low diagnosis rate. The GAD therapeutics market has many FDA approved therapies available for treatment including SSRIs, TCAs, SNRIs, benzodiazepines and buspirone. The therapies which are available for the treatment of GAD have shown moderate efficacy and safety profiles which have lead to moderate unmet need. The market is open for novel entrants to fulfill the unmet need of the GAD therapeutics market. GlobalData, the industry analysis specialist, has released its new report, “Generalized Anxiety Disorders (GAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Generalized Anxiety Disorders (GAD) Therapeutics market. The report identifies the key trends shaping and driving the global Generalized Anxiety Disorders (GAD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Generalized Anxiety Disorders (GAD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number